State Street’s Rani Therapeutics RANI Stock Holding History

State Street’s Portfolio RANI Stock Details RANI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$313K	Buy	395,642 +22,500	+6%	+$17.9K	﹤0.01%	3779
2026 Q2	$284K	Hold	373,142	–	–	﹤0.01%	3799
2026 Q1	$274K	Sell	373,142 -13,900	-4%	-$17.8K	﹤0.01%	3816
2025 Q4	$523K	Buy	387,042 +324,600	+520%	+$490K	﹤0.01%	3664
2025 Q3	$31.2K	Hold	62,442	–	–	﹤0.01%	4210
2025 Q2	$32.1K	Hold	62,442	–	–	﹤0.01%	4159
2025 Q1	$78.7K	Hold	62,442	–	–	﹤0.01%	4020
2024 Q4	$85.5K	Buy	62,442 +20,400	+49%	+$42.9K	﹤0.01%	4020
2024 Q3	$90.8K	Hold	42,042	–	–	﹤0.01%	3992
2024 Q2	$160K	Buy	42,042 +8,300	+25%	+$43K	﹤0.01%	3879
2024 Q1	$105K	Hold	33,742	–	–	﹤0.01%	4026
2023 Q4	$112K	Hold	33,742	–	–	﹤0.01%	4036
2023 Q3	$73.4K	Buy	33,742 +1,800	+6%	+$6.88K	﹤0.01%	4188
2023 Q2	$132K	Hold	31,942	–	–	﹤0.01%	4139
2023 Q1	$165K	Hold	31,942	–	–	﹤0.01%	4138
2022 Q4	$188K	Buy	31,942 +5,800	+22%	+$42.3K	﹤0.01%	4127
2022 Q3	$250K	Hold	26,142	–	–	﹤0.01%	4039
2022 Q2	$270K	Hold	26,142	–	–	﹤0.01%	4079
2022 Q1	$353K	Buy	26,142 +6,442	+33%	+$107K	﹤0.01%	4183
2021 Q4	$322K	Hold	19,700	–	–	﹤0.01%	4164
2021 Q3	$351K	Buy	+19,700	New	+$341K	﹤0.01%	4116

Other funds holding RANI

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Kestra Private Wealth Services Austin, Texas $9.37B AUM 22.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Luther King Capital Management (LKCM) Fort Worth, Texas $24.3B AUM 19.37% 1-Year Est. Return

Well Done LLC Holland, Michigan $732M AUM 14.62% 1-Year Est. Return

MOTCO San Antonio, Texas $1.22B AUM 20.31% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

State Street's RANI Position: Q3 2026 in Review

State Street increased its Rani Therapeutics (RANI) stake by 6% in Q3 2026, buying an estimated $17.9K and bringing the position to 395,642 shares worth $313K. The position accounts for ﹤0.01% of the portfolio, ranked #3779.

State Street first reported a position in RANI in Q3 2021 and has held it in 21 quarters since. The position peaked at $523K in Q4 2025. 33 funds tracked by Wall St. Rank hold RANI as of Q3 2026.

State Street held 395,642 shares of Rani Therapeutics worth $313K as of Q3 2026.
State Street bought 22,500 Rani Therapeutics shares in Q3 2026, an estimated $17.9K.
Rani Therapeutics made up ﹤0.01% of State Street's portfolio in Q3 2026, its #3779 holding.
State Street first reported a position in Rani Therapeutics in Q3 2021 and has held it in 21 quarters since.
State Street's Rani Therapeutics position peaked at $523K in Q4 2025.
33 funds tracked by Wall St. Rank held Rani Therapeutics as of Q3 2026.

Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.